What's Happening?
Retham Technologies, a diagnostics company, has launched its new product, Retham Cryoplatelets, designed to address challenges in platelet-based research. These cryopreserved platelets offer a stable and consistent source of functional human platelets, overcoming
issues related to donor variability and logistical complexities associated with fresh platelets. Prolytix, a leader in coagulation and hematology services, has been named the distributor for these cryoplatelets. The product is intended for research use only and supports various applications, including platelet function assays and drug screening. This development is seen as a significant advancement for laboratories seeking improved reproducibility and efficiency in their research.
Why It's Important?
The introduction of Retham Cryoplatelets is significant for the research community, particularly in the fields of hematology and biotherapeutics. By providing a reliable and scalable source of platelets, Retham addresses a critical need for consistent research materials, which can enhance the reproducibility of experiments and reduce costs associated with fresh platelet procurement. This innovation could accelerate research in drug development and other platelet-related studies, potentially leading to new therapeutic discoveries and improved patient outcomes. The partnership with Prolytix, known for its expertise in the field, further strengthens the product's market reach and application potential.
